Holen Sie sich die Stockscreener-App
4.84
1.47%
0.07
Handel nachbörslich:
4.85
0.010
+0.21%
Quoin Pharmaceuticals Ltd Adr Aktie (QNRX) Neueste Nachrichten
Quoin Pharmaceuticals Provides Corporate Update and Reports First Quarter 2026 Financial Results - Sahm
Quoin Pharmaceuticals initiated with a Buy at Lucid Capital - TipRanks
Quoin Pharmaceuticals to Announce Corporate Update and First Quarter 2026 Financial Results on Thursday, May 7, 2026 - Sahm
Quoin Pharmaceuticals DRC News Today (QNRX) - Investing.com
Quoin Pharmaceuticals provides regulatory update on QRX009 topical rapamycin - TipRanks
CORRECTION -- Quoin Pharmaceuticals Provides Clinical and Regulatory Update for QRX009 Topical Rapamycin Development Programs - Sahm
Quoin Pharmaceuticals price target raised to $35 from $25 at Alliance Global - TipRanks
Quoin Pharmaceuticals (NASDAQ: QNRX) advances NS drug but warns on cash - Stock Titan
Quoin Pharmaceuticals provides update following QRX003 Type C meeting with FDA - TipRanks
Quoin Pharmaceuticals to Announce Corporate Update and Fourth Quarter and Full-Year 2025 Financial Results on Thursday, March 26, 2026 - ChartMill
Quoin Pharmaceuticals Announces FDA Grants Fast Track Designation for QRX003 for the Treatment of Netherton Syndrome - Sahm
Maxim Group Sticks to Its Buy Rating for Quoin Pharmaceuticals (QNRX) - The Globe and Mail
Analysts’ Opinions Are Mixed on These Healthcare Stocks: CalciMedica (CALC) and Talphera (TLPH) - The Globe and Mail
Quoin Pharmaceuticals highlights continued growth of NETHERTON NOW program - TipRanks
Critical Contrast: Amneal Pharmaceuticals (NASDAQ:AMRX) versus Quoin Pharmaceuticals (NASDAQ:QNRX) - Defense World
This Quoin Pharmaceuticals Insider Increased Their Holding By 1,515,200% Last Year - Sahm
Quoin seeks orphan drug status in Japan for Netherton Syndrome therapy By Investing.com - Investing.com India
Quoin seeks orphan drug status in Japan for Netherton Syndrome therapy - Investing.com
Quoin Pharmaceuticals Announces Submission to Japanese MHLW for Orphan Drug Designation for QRX003 in Netherton Syndrome - Sahm
Quoin Pharmaceuticals Files Breakthrough Medicine Designation Application in Saudi Arabia for QRX003 in Netherton Syndrome - ChartMill
ETFs Investing in Quoin Pharmaceuticals. Ltd Sponsored ADR Stocks - TradingView — Track All Markets
Quoin Pharmaceuticals Ltd – ADR trading resumes - MSN
Quoin Pharmaceuticals (NASDAQ:QNRX) Shares Up 24.5% – Still a Buy? - Defense World
Pre Market Movers: PRAX, SPRC, QNRX Set The Pace - RTTNews
Wall Street analysts’ outlook for Quoin Pharmaceuticals Ltd ADR (QNRX) - setenews.com
US Stocks Mixed; Sea Shares Gain After Q3 ResultsMSP Recovery (NASDAQ:MSPR), Outset Medical (NASDAQ:OM) - Benzinga
Quoin Pharmaceuticals Announces Corporate Update and Third Quarter 2025 Financial Results - Sahm
Quoin Pharmaceuticals director Langer buys $128,640 in ADSs - Investing.com
Why NioCorp Developments Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket - Benzinga
Quoin Pharma (QNRX) Stock Skyrockets 150% on Funding Deal – What’s Next? - ts2.tech
Quoin Pharmaceuticals stock soars after securing premium-priced funding - Investing.com
Why New Fortress Energy Shares Are Trading Higher By 41%; Here Are 20 Stocks Moving Premarket - Sahm
Quoin Pharmaceuticals Releases Fifth NETHERTON NOW Video Featuring Writers and Influencers Allie and Kaleigh Fasanella, Twin Sisters Living with Netherton Syndrome - ChartMill
Quoin Pharmaceuticals finalizes separation agreement with former CFO - Investing.com
Quoin Pharmaceuticals’ NETHERTON NOW Campaign Surpasses One Million Video Views, Amplifying Global Awareness of Netherton Syndrome - ChartMill
Quoin Pharmaceuticals advances rare disease pipeline with two active trials - Investing.com
Quoin Pharmaceuticals (QNRX) FDA Approvals, PDUFA Dates & Drug Alerts 2026 - MarketBeat
QNRX Stock: Price, Forecast, Financials & AI Analysis - Intellectia AI
Quoin Pharmaceuticals regains Nasdaq compliance By Investing.com - Investing.com India
Quoin Pharmaceuticals regains Nasdaq compliance - Investing.com
Quoin Pharmaceuticals Ltd Share Price ADR EACH REPR 35 ORD SPON - Hargreaves Lansdown
QNRX Stock Plummets to 52-Week Low of $0.17 Amid Market Struggles - Investing.com
Quoin Pharmaceuticals CEO Michael Myers acquires $250,000 in shares - Investing.com
Quoin Pharmaceuticals granted extension to meet Nasdaq listing - Investing.com
Quoin Pharmaceuticals (QNRX) Stock Trends and Sentiment 2025 - MarketBeat
Quoin Pharmaceuticals (QNRX) Stock Forecast and Price Target 2026 - MarketBeat
Quoin Pharmaceuticals sets terms for $6.5 million offering - Investing.com India
symbol__ Stock Quote Price and Forecast - CNN
Tuesday's session: gap up and gap down stocks - ChartMill
Quoin Pharmaceuticals LtdADR (QNRX) News, Articles, Events & Latest Updates - Stocktwits
What is the current Price Target and Forecast for Quoin Pharmaceuticals (QNRX) - Zacks Investment Research
QNRX Forecast — Price Target — Prediction for 2027 - TradingView — Track All Markets
Endo (ENDP) Inks Deal to Develop Rare Disease Drug in Canada - Yahoo Finance
Top movers in Friday's pre-market session - ChartMill
What's going on in today's pre-market session - ChartMill
These stocks have an unusual volume in today's session - ChartMill
QNRX Stock Price, Quote & Chart | QUOIN PHARMACEUTICALS LT-ADR (NASDAQ:QNRX) - ChartMill
Quoin Pharmaceuticals (QNRX) Short Interest & Short Float | Updated May 2026 - MarketBeat
QNRXQuoin Pharmaceuticals Ltd ADR Stock Price and Quote - Finviz
QNRX Stock Price and Chart — NASDAQ:QNRX - TradingView
QNRX: Quoin Pharmaceuticals LtdADR Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
Quoin Pharmaceuticals, Ltd. (QNRX) Stock Price, News, Quote & History - ca.finance.yahoo.com
Technical Analysis of Quoin Pharmaceuticals. Ltd Sponsored ADR (NASDAQ:QNRX) - TradingView — Track All Markets
Quoin Pharmaceuticals (QNRX) Earnings Date and Reports 2026 - MarketBeat
Quoin Pharmaceuticals (QNRX) Stock Price, News & Analysis - MarketBeat
Top Quoin Pharmaceuticals (QNRX) Competitors 2026 - MarketBeat
Experience real-time quotes, in-depth charts, and analyst ratings - webull.com
APOP Financial Statements & ChartsQuoin Pharmaceuticals LtdAdr MacroTrends - CMLviz
0.98%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):